Dupilumab_Metastatic NSCLC
This is an Phase Ib/2 study, single arm, single cohort study to determine the safety and
tolerability of Dupilumab with PD-(L)1 blockade for patients with relapsed/refractory
metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1...
Age: 18 years - 66+
Gender: All
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in
participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon
19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI...
Age: 18 years - 66+
Gender: All
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.
Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted
therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the
co...
Age: 18 years - 66+
Gender: All
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a
different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial
have either spread to other parts of the body (metastatic) or cannot be removed c...
Age: 18 years - 66+
Gender: All
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in
combination with tiragolumab compared with durvalumab in participants with locally advanced,
unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two
...
Age: 18 years - 66+
Gender: All
First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat)
administered via intravenous infusion or via subcutaneous injection as a single agent and in
...
Age: 18 years - 66+
Gender: All
Study of SRF388 in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.
Age: 18 years - 66+
Gender: All
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm
the safety of VV1 in combination with cemiplimab. The study will enroll patients with two
distinct advanced malignancies in separate tumor cohorts. The two cancers types ar...
Age: 18 years - 66+
Gender: All
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
This trial studies how well atezolizumab added to the usual radiation therapy works in
treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the cancer,...
Age: 18 years - 66+
Gender: All
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment
with that of platinum-based chemotherapy in participants with locally advanced or metastatic
non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor rece...
Age: 18 years - 66+
Gender: All
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
The purpose of this research study is to study the effect of giving nivolumab with
CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining
if this medicine results in:
1. A significant immune response against their tumor (which t...
Age: 18 - 99 years
Gender: All
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have
progressed following prior therapy. This is the first time this drug is tested in patients,
and so it will help to understand what type of side effects may occur with the drug
t...
Age: 18 years - 66+
Gender: All
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
The purpose of this study is to assess the efficacy and safety of stereotactic body
radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with
unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
The p...
Age: 18 years - 66+
Gender: All
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of c...
Age: 18 years - 66+
Gender: All
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human
immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not
respond to treatment (refractory), or have distributed over a large area in the b...
Age: 18 years - 66+
Gender: All
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA
non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in
a patient's tumor cells may help doctors select the best treatment for patients that h...
Age: 18 years - 66+
Gender: All